Skip to Content
CellsCells
  • Review
  • Open Access

10 March 2026

23 Pages

Re-Tooling of γδ T Cells for Cancer Immunotherapy Using Advanced Manufacturing and Genetic Engineering

and
1
University of Edinburgh Medical School, University of Edinburgh, Little France Crescent, Edinburgh EH16 4UU, UK
2
Department of Precision and Population Oncology, Guy’s Hospital, King’s College London, London SE1 9RT, UK
3
Leucid Bio Ltd., Guy’s Hospital, Great Maze Pond, London SE1 9RT, UK
4
Department of Immunology, Eastbourne Hospital, Kings Drive, Eastbourne BN21 2UD, UK

Abstract

Adoptive immunotherapy using ex-vivo-amplified autologous αβ T cells has achieved notable success in the treatment of diverse cancer types. Pre-eminent among these developments has been the advent of chimeric antigen receptor (CAR) T cell therapy, which has revolutionised the treatment of selected haematological malignancies. However, autologous CAR T cell immunotherapy is poorly scalable and has demonstrated limited efficacy against solid tumours. Accordingly, there has been significant interest in alternative strategies that may bridge these gaps. The use of γδ T cells is an attractive alternative since they possess intrinsic anti-tumour activity and do not elicit graft versus host disease (GvHD) when employed as an allogeneic drug product. In this review, we evaluate the potential use of γδ T cells for cancer immunotherapy and how manufacturing and genetic engineering refinements can be used to potentiate this activity. We also summarise current clinical experience with CAR γδ T cell therapies and discuss the implications of these findings for the next generation of cellular immunotherapies.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.